Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia

Objective To investigate the intravenous human immunoglobulin therapy in renal transplant recipients with moderate to severe pulmonary infection.Methods From October 2005 to July 2015,48 patients with moderate to severe pulmonary infection after renal transplantation in our department were analyzed....

Full description

Saved in:
Bibliographic Details
Main Authors: ZHU Bo-cheng, GE Guo-jun, REN Wen-li, LOU Bo-yang, ZHU Xiao-feng
Format: Article
Language:zho
Published: Editorial Department of Journal of Clinical Nephrology 2017-01-01
Series:Linchuang shenzangbing zazhi
Subjects:
Online Access:http://www.lcszb.com/thesisDetails?columnId=57917343&Fpath=home&index=0
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850143171753803776
author ZHU Bo-cheng
GE Guo-jun
REN Wen-li
LOU Bo-yang
ZHU Xiao-feng
author_facet ZHU Bo-cheng
GE Guo-jun
REN Wen-li
LOU Bo-yang
ZHU Xiao-feng
author_sort ZHU Bo-cheng
collection DOAJ
description Objective To investigate the intravenous human immunoglobulin therapy in renal transplant recipients with moderate to severe pulmonary infection.Methods From October 2005 to July 2015,48 patients with moderate to severe pulmonary infection after renal transplantation in our department were analyzed.Twenty patients given daily intravenous human immunoglobulin(20 g for 3to 7 days)were taken as the treatment group,and the rest 23 patients without given intravenous human immunoglobulin served as the control group.The basic immunosuppressant was given in both two groups.The infection control time,fatality rate,length of hospital stay,and the occurrence of acute rejection and other indicators were observed in both two groups.Results The infection control time in the treatment group was significantly shorter than in the control group[(11.78±3.30)d vs.(15.13±3.30)d,P=0.004)].Twenty-three cases survived and2 died in the treatment group,and16 cases survived and 7 died in the control group with the difference being statistically significant(P=0.047).There was no significant difference in the length of hospital stay between the treatment group and the control group[(32.78±13.93)d vs.(30±23.87)d].There was no acute rejection in the treatment group,and 2 cases of acute rejection in the control group.Conclusions Intravenous human immunoglobulin can significantly reduce fatality rate of the renal transplant recipients with moderate to severe pulmonary infection and can significantly shorten the time of infection control.
format Article
id doaj-art-bf9604a6e35d499590a16f9bd7fe5fcc
institution OA Journals
issn 1671-2390
language zho
publishDate 2017-01-01
publisher Editorial Department of Journal of Clinical Nephrology
record_format Article
series Linchuang shenzangbing zazhi
spelling doaj-art-bf9604a6e35d499590a16f9bd7fe5fcc2025-08-20T02:28:49ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902017-01-0141541857917343Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumoniaZHU Bo-chengGE Guo-junREN Wen-liLOU Bo-yangZHU Xiao-fengObjective To investigate the intravenous human immunoglobulin therapy in renal transplant recipients with moderate to severe pulmonary infection.Methods From October 2005 to July 2015,48 patients with moderate to severe pulmonary infection after renal transplantation in our department were analyzed.Twenty patients given daily intravenous human immunoglobulin(20 g for 3to 7 days)were taken as the treatment group,and the rest 23 patients without given intravenous human immunoglobulin served as the control group.The basic immunosuppressant was given in both two groups.The infection control time,fatality rate,length of hospital stay,and the occurrence of acute rejection and other indicators were observed in both two groups.Results The infection control time in the treatment group was significantly shorter than in the control group[(11.78±3.30)d vs.(15.13±3.30)d,P=0.004)].Twenty-three cases survived and2 died in the treatment group,and16 cases survived and 7 died in the control group with the difference being statistically significant(P=0.047).There was no significant difference in the length of hospital stay between the treatment group and the control group[(32.78±13.93)d vs.(30±23.87)d].There was no acute rejection in the treatment group,and 2 cases of acute rejection in the control group.Conclusions Intravenous human immunoglobulin can significantly reduce fatality rate of the renal transplant recipients with moderate to severe pulmonary infection and can significantly shorten the time of infection control.http://www.lcszb.com/thesisDetails?columnId=57917343&Fpath=home&index=0Renal transplantationPulmonary infectionHuman immunoglobulin
spellingShingle ZHU Bo-cheng
GE Guo-jun
REN Wen-li
LOU Bo-yang
ZHU Xiao-feng
Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
Linchuang shenzangbing zazhi
Renal transplantation
Pulmonary infection
Human immunoglobulin
title Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
title_full Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
title_fullStr Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
title_full_unstemmed Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
title_short Efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
title_sort efficacy of intravenous human immunoglobulin in renal transplant recipients with moderate to severe pneumonia
topic Renal transplantation
Pulmonary infection
Human immunoglobulin
url http://www.lcszb.com/thesisDetails?columnId=57917343&Fpath=home&index=0
work_keys_str_mv AT zhubocheng efficacyofintravenoushumanimmunoglobulininrenaltransplantrecipientswithmoderatetoseverepneumonia
AT geguojun efficacyofintravenoushumanimmunoglobulininrenaltransplantrecipientswithmoderatetoseverepneumonia
AT renwenli efficacyofintravenoushumanimmunoglobulininrenaltransplantrecipientswithmoderatetoseverepneumonia
AT louboyang efficacyofintravenoushumanimmunoglobulininrenaltransplantrecipientswithmoderatetoseverepneumonia
AT zhuxiaofeng efficacyofintravenoushumanimmunoglobulininrenaltransplantrecipientswithmoderatetoseverepneumonia